The Legal and Regulatory Framework

The United Kingdom occupies a paradoxical position in the global cannabis and psychedelic medicines landscape. It is among the world’s largest exporters of medicinal cannabis, yet domestic patients face significant barriers to accessing cannabis-based products for medicinal use (CBPMs), especially through the National Health Service (NHS). The UK hosts some of the world’s most advanced psychedelic medicines research at institutions, yet those very researchers operate under arguably the most restrictive licensing regime applicable to any developed-world scientific community. In addition to setting out the UK’s drug laws in so far as they relate to cannabis and psychedelic medicines, this guide considers some of the practical barriers to entering and operating within the UK market as it currently stands.

The Misuse of Drugs Act 1971 and Classification

The Misuse of Drugs Act 1971 (MDA) remains the cornerstone of the UK’s controlled drugs regime. It creates a tiered classification system – Class A, B and C – that determines both the range of criminal offences and the maximum sentences available to courts. It also creates the legal mechanism by which the UK Home Office can license otherwise unlawful activities relating to controlled drugs.

Cannabis is a Class B controlled drug. This means that the principal offences of possession, supply, production, cultivation, importation and exportation are all engaged in respect of any part of the cannabis plant falling within the statutory definition, save for certain specifically excluded parts. As a Class B drug, production and supply of cannabis and possession of cannabis with intent to supply carry maximum sentences of 14 years’ imprisonment, while simple possession carries a maximum of five years. The court must also have regard to sentencing guidelines, under which the quantity and value of drugs, and the degree of involvement of the accused, are factored into the process. The Sentencing Council guidelines in respect of possession of a controlled drug cite the use of cannabis to help with a diagnosed medical condition as a recognised mitigating factor. 

Psychedelic substances – including psilocybin (the active compound in so-called magic mushrooms), psilocin, LSD, DMT and MDMA – are classified as Class A controlled drugs, attracting the most serious penalties: up to life imprisonment for production and supply, and up to seven years for simple possession.

Importantly, the MDA draws a distinction between classification (which determines the severity of offences and sentences) and scheduling under the Misuse of Drugs Regulations 2001 (MDRs) (which determines whether and how a substance may be lawfully used, prescribed, or handled for research purposes). A drug may be Class A and yet be available for prescription (eg, heroin (diamorphine)). Conversely, a drug may be rescheduled to facilitate research or prescribing without any change to its criminal classification.

The MDRs – Scheduling

The MDRs operate alongside the MDA to create a five-schedule licensing and authorisation system. The schedules run from Schedule 1 (the most restrictive – substances deemed to have no therapeutic value) to Schedule 5 (the least restrictive – preparations exempt from most controls). The practical effect of the schedule in which a substance sits determines:

• whether it may be prescribed;
• who may prescribe it;
• the documentation requirements; and
• what Home Office licensing is needed for research, manufacture or supply.

The rescheduling of a substance from Schedule 1 to a lower schedule does not decriminalise it, nor can it create a recreational market. It simply creates a pathway for legitimate medical or research use within a tightly regulated framework. The rescheduling of cannabis-based products for medicinal use from Schedule 1 to Schedule 2 in 2018 is a good example of this mechanism in practice.

The Human Medicines Regulations 2012

The Human Medicines Regulations 2012 (HMRs) govern the authorisation, manufacture, importation, distribution and supply of medicinal products (defined to include “any substance… presented as having properties of preventing or treating disease”) in the UK. They operate in parallel with the MDA and MDRs: compliance with the HMRs does not in itself provide a defence under the MDA, and vice versa.

For operators in the cannabis and psychedelic medicines space, the HMRs create an extensive range of offences. These include:

• manufacture or assembly of medicinal products without a manufacturer’s licence;
• wholesale dealing without a wholesale dealer’s licence;
• sale or supply of a prescription-only medicine without a valid prescription; and
• sale or supply of any unauthorised (unlicensed) medicinal product.

The sanctions are serious – the most significant offences under the HMRs carry terms of imprisonment of up to two years, as well as unlimited fines.

The Psychoactive Substances Act 2016

The Psychoactive Substances Act 2016 (PSA) was enacted to address the phenomenon of “legal highs” – synthesised substances designed to mimic the effects of controlled drugs, but falling outside the MDA because they did not match the precise chemical definitions of scheduled substances. The PSA creates a broad range of offences in relation to any substance capable of producing a psychoactive effect if consumed, subject to specific exemptions.

The PSA is of particular relevance to operators in the synthetic cannabinoid and novel psychoactive substance space. Any activity involving a synthetic version of cannabis which is psychoactive but does not fall within the Class B definition under the MDA is likely to be an offence under the PSA. Crucially, medicinal products (as defined in the HMRs) are among the exempted substances under Schedule 1 of the PSA – but this exemption is strictly construed. The Court of Appeal in R v Chapman [2017] EWCA Crim 1743 confirmed that a product may be a medicinal product for one purpose but not another, and courts will look closely at the chemical composition and intended use of any product claimed to fall within the exemption.

Cannabis-Based Products for Medicinal Use (CBPMs)

Background: the 2018 rescheduling

The legal landscape of medicinal cannabis in the UK was transformed in November 2018 by the rescheduling of cannabis-based products for medicinal use from Schedule 1 to Schedule 2 of the MDRs, pursuant to the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (the “2018 Regulations”).

The impetus for reform came largely from a series of high-profile cases involving seriously ill children. In early 2018, the case of Alfie Dingley – a young boy with severe epilepsy whose family had accessed cannabis oil in the Netherlands with dramatic therapeutic benefit, and whose Home Office licence application was refused – attracted wide public attention. Later that year, cannabis oil was confiscated from Charlotte Caldwell at Heathrow Airport; her son Billy, a severely epileptic 12-year-old, was subsequently hospitalised with serious seizures previously controlled by cannabis oil.

The 2018 Regulations created the current framework, following a two-part review: the first led by the then Chief Medical Officer for England, who found conclusive evidence of therapeutic benefit for certain conditions including chronic pain, chemotherapy-induced nausea and vomiting, and MS spasticity; and the second by the Advisory Council on the Misuse of Drugs (ACMD).

Definition of CBPMs

The regulatory definition of a CBPM, as inserted by the 2018 Regulations into Regulation 2(1) of the MDRs, is precise. A product is a CBPM if it:

• is or contains cannabis, cannabis resin, cannabinol (CBD) or a CBD derivative (not being dronabinol or its stereoisomers);
• is produced for medicinal use in humans; and
• is either a medicinal product as defined in the HMRs, or a substance or preparation for use as an ingredient of a medicinal product.

All three limbs must be satisfied. Whether a given product meets the definition requires careful legal analysis of its composition, intended purpose and manufacturing process.

The Three Routes to Lawful Access

Route 1: unlicensed “special” prescription

Most CBPMs prescribed in the UK have no marketing authorisation – they are “unlicensed specials”. An unlicensed CBPM can only be prescribed by a doctor on the General Medical Council (GMC)’s Specialist Register, or by another prescribing professional acting under the instruction of such a specialist. General practitioners (GPs) cannot initiate CBPM prescriptions, though they may continue prescriptions initiated by a specialist under “shared care” arrangements.

Route 2: clinical trials

Unlicensed CBPMs may be used in clinical trials, subject to compliance with the Clinical Trial Regulations. This route is critically important for the development of a clinical-evidence base sufficient to support NHS commissioning and, ultimately, marketing authorisation.

Route 3: licensed (marketing authorisation) products

Once a CBPM has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), it may be prescribed by any practitioner with the appropriate authority under the MDRs. Currently only three cannabis-derived medicines hold marketing authorisation in the UK: Sativex (nabiximols – Schedule 4); Epidyolex (purified cannabidiol (CBD) – Schedule 5); and Nabilone (Schedule 2).

Prohibition on Smoking: Permitted Administration Routes

Regulation 16A(3) of the MDRs (as amended) prohibits the smoking of CBPMs other than for research purposes under licence. Lawful routes of administration include vaporisation (vaping), oral oils, capsules and tinctures.

The Controlled Drugs Licensing Regime

Prospective applicants must first register on the Home Office controlled drugs licensing system before submitting an application for consideration by the Drugs and Firearms Licensing Unit (DFLU). Every named person on the application must hold a valid Disclosure and Barring Service (DBS) check (which will confirm, for example, whether a person has criminal convictions). The application must cover:

• the intended purpose of the licence;
• key personnel (including those responsible for security, legal compliance and regulatory affairs);
• the full production and supply chain;
• physical security measures (including CCTV, alarm systems and secure storage); and
• standard operating and record-keeping procedures.

All new applicants and new sites for existing licensees are subject to a pre-licence site visit by a DFLU Compliance Officer. The Home Office targets a 16-week processing period for new applications and a site visit to take place, but timelines can be considerably longer in practice. Licences are valid for 12 months and must be renewed at least six weeks before expiry.

The Misuse of Drugs (Fees) Regulations 2010 set the Home Office fee structure for licences issued under the MDRs. They differentiate between cultivation of cannabis high in tetrahydrocannabinol (THC) (treated as a controlled drug activity requiring a full controlled drugs licence with higher fees and stricter scrutiny) and low-THC industrial hemp cultivation (licensed under a distinct, lower-cost regime where THC content must not exceed the permitted limit, which is currently 0.2%; the ACMD has recommended a rise to 0.3%, but the required statutory instrument  has not yet been made). The framework reflects differing risk profiles, with hemp subject to lighter-touch regulation but still requiring annual licensing and compliance monitoring.

Types of Controlled Drug Licence

The type of licence required depends on the substance concerned and the proposed activities.

• Schedule 1 licence: required for research involving cannabis (as opposed to CBPMs), psilocybin, LSD, MDMA and other Schedule 1 drugs. These licences are issued for “research or other special purpose” only and do not confer any right to prescribe or supply commercially.
• Schedule 2 licence: required for activities involving CBPMs. These licences permit possession, production, supply and cultivation of Schedule 2 substances, subject to conditions.
• Industrial hemp (low-THC) cultivation licence: available for the cultivation of cannabis varieties within the permitted THC threshold – currently 0.2% (as above) – for defined industrial end uses. Only the non-controlled parts of the plant (mature stalk and seeds) may be utilised.
• Import/export licence: required for each individual consignment of controlled drugs, in addition to the underlying domestic licence. Import licences are valid for three months; export licences for two months or the duration of the importing country’s permit, whichever is shorter.

Import and Export

The MHRA actively monitors CBPM imports and may refuse or delay consignments where product standards or documentation are deficient. Bulk quantities of CBD and “pure” CBD isolate are routinely seized at the border by HM Revenue & Customs (HMRC) and UK Border Force on suspicion that they may nevertheless contain THC.

CBD

Legal status of CBD

CBD is one of at least 144 naturally occurring cannabinoids found in the cannabis plant. Unlike THC, CBD is not itself a controlled drug under the MDA, and it does not produce the psychoactive effects associated with recreational cannabis use.

However, the legal status of CBD-containing products in the UK is substantially more complex than is commonly understood. The Home Office position is that isolating pure CBD without any trace of THC or other controlled cannabinoids is extremely difficult in practice. As a result, a product containing CBD is likely to be treated as a controlled substance under the MDA if it contains any controlled cannabinoid at a level sufficient to engage the legislation. The Home Office originally issued guidance to this effect in August 2019.

An argument has developed within the industry that CBD products containing less than 0.2% THC (as above) are lawful, on the basis that they are produced from non-controlled parts of EU-approved cannabis varieties. The legal foundation of this argument is fragile: the THC threshold under the industrial hemp regime was intended to identify which cannabis varieties may be cultivated for industrial purposes, not to create a general exemption for consumer CBD products. The matter has not been litigated (unlike the related issue of “exempt products”; see below). In practical terms, there is an almost total absence of enforcement against domestic retailers of low-THC CBD products, suggesting regulatory tolerance – but this does not confer legal immunity.

CBD as a medicinal product

Where CBD is used for medicinal purposes (or, noting the definition in the HMRs, presented as having medicinal uses), the MHRA has classified such products as medicines since 2016, requiring marketing authorisation before they may be sold, supplied or advertised in the UK, unless exempt under Regulation 167 of the HMRs. The only CBD product currently holding MHRA marketing authorisation is Epidyolex, a purified CBD oral solution prescribed for severe epilepsy. Marketing CBPMs or CBD medicinal products without authorisation is an offence under the HMRs.

THC trace limits in CBD products

In December 2021 the ACMD recommended a threshold of 50 μg of THC per unit of consumption in CBD products. The government accepted this recommendation in October 2023 and agreed in principle to introduce a statutory THC cap. However, as of April 2026, no implementing legislation has been introduced. The current operative standard remains the 1 mg THC per product container limit under the “exempt product” definition in Regulation 2(1) of the MDRs (which, in turn, means the usual prohibitions are disapplied by Regulation 4(5)), reiterated in Home Office guidance issued in October 2024. CBD product manufacturers must continue to rely on this existing framework pending clearer regulation.

Jersey Hemp, a Channel Islands CBD producer, closed in 2023 after the Home Office wrongly concluded that its products were controlled substances by virtue of their THC content. This was despite Jersey Hemp’s position that their products satisfied the “exempt products” criteria in Regulation 2(1) of the MDRs. Jersey Hemp judicially reviewed the Home Office and Government of Jersey, arguing that its products met the three-limbed criteria, as they were designed to administer CBD, not THC. The Home Office conceded in early 2024, admitting it had misinterpreted its own regulations. However, because the government conceded rather than contested the case to judgment, no binding legal precedent was formally established, leaving regulatory ambiguity unresolved industry-wide.

Psychedelic Medicines

Current legal status

Psychedelic substances occupy the most restrictive category of the UK drug control regime. With the notable exception of ketamine, all classical psychedelics – psilocybin (and psilocin), LSD, DMT, mescaline and MDMA – are classified as Class A, Schedule 1 drugs under the MDA and MDRs respectively. This “double designation” means they attract the most severe criminal penalties (up to life imprisonment for supply) and are treated as having no recognised therapeutic value, permitting only tightly licensed research.

Ketamine is currently classified as Class B, Schedule 3. The government is actively considering reclassifying ketamine to Class A, driven by concerns over rising recreational use and associated health risks. A small number of private clinics in the UK – primarily in London – offer ketamine-assisted therapy for treatment-resistant depression and anxiety, prescribed off-label under the existing framework. The most prominent such clinic, Awakn, closed in 2024, citing insufficient demand.

The pathway to psychedelic medicines

Looking ahead, two potential legal pathways exist by which psychedelic medicines could become accessible in the UK. The first – and more likely in the near to medium term – is a rescheduling analogous to that applied to CBPMs in 2018: movement from Schedule 1 to Schedule 2, enabling prescription by specialist doctors as unlicensed “specials” pending marketing authorisation. This approach has been adopted by Australia, which approved both psilocybin (for treatment-resistant depression) and MDMA (for post-traumatic stress disorder (PTSD)) for prescription by authorised psychiatrists from February 2023.

The second and more definitive route is the conventional licensing pathway: completion of clinical trials and receipt of marketing authorisation from the MHRA, whereupon the psychedelic medicine would be subject to the same law as any other licensed medicine. An ACMD commissioning letter of June 2025 explicitly identified psychedelics, and psilocybin in particular, as a policy area to be informed by the review of the CBPM framework – a significant signal of regulatory intent. The letter makes reference to barriers to research with Schedule 1 drugs and the lessons that have been learnt to date through the reclassification of CBPMs. It also specifically cites the potential use of psilocybin and other controlled drugs to treat depression.

Devolved Administrations: Scotland and Northern Ireland

A frequently repeated misconception is that cannabis or drug law differs materially between the four nations of the UK. This is incorrect as a matter of law. The MDA 1971 and the MDRs 2001 are reserved legislation, enacted by the Westminster Parliament, and apply uniformly in England, Wales, Scotland and Northern Ireland. Consequently, the devolved administrations in Edinburgh, Cardiff and Belfast have no legislative competence to alter drug classification, scheduling, or the criminal offences and penalties applicable to controlled drugs. Any such change in the law remains solely within the competence of the UK Parliament. For any regional variations to drug-related laws and regulations, Statutory Instruments are used. (For example, the Misuse of Drugs (Amendment No 2) Regulations) Northern Ireland 2018 (the “NI Regulations 2018”) is the parallel instrument to the 2018 Regulations, which have effect in England, Wales and Scotland.) 

Scotland

The criminal law framework – including the classification of cannabis as Class B, the Schedule 1 status of psychedelics, and all associated offences and penalties – is identical in Scotland to the rest of Great Britain. The 2018 Regulations rescheduling CBPMs applied to England, Wales and Scotland. Scotland has historically been more likely to issue cannabis warnings or direct individuals to drug diversion programmes rather than prosecute for minor possession, pursuant to the Lord Advocate’s guidelines. However, Scotland cannot formally decriminalise possession as a matter of law, as drug law remains reserved to Westminster.

Health policy is devolved and the responsibility of the Scottish government, which creates some differences in how CBPMs are commissioned and funded through NHS Scotland compared with NHS England. In practice, the access challenges – and the dominance of private prescribing – are broadly similar across the UK.

Northern Ireland

Drug law is in part a devolved matter in Northern Ireland (unlike Scotland and Wales, where it is fully reserved). The 2018 Regulations applying in England, Wales and Scotland did not automatically extend to Northern Ireland; equivalent regulations specific to Northern Ireland – the NI Regulations 2018 – were subsequently enacted and came into force in substantively the same terms.

The practical framework for prescribing and accessing CBPMs in Northern Ireland is therefore materially the same as in the rest of the UK, though implemented through devolved instruments. Healthcare commissioning and access to CBPMs through the Health and Social Care Board in Northern Ireland follows its own processes. Business operators entering the Northern Ireland market should verify the applicable regulatory instruments and licensing requirements against the Northern Ireland-specific statutory framework.

The Home Office

The Home Office, acting via its Drugs and Firearms Licensing Unit (DFLU), is responsible for issuing controlled drug licences under the MDA and MDRs. The Secretary of State’s powers are broad: under Section 7(1)(b) of the MDA, regulations may be made permitting activities – including production, supply, possession and cultivation – that would otherwise constitute criminal offences. The DFLU is then responsible for exercising those powers and administering the controlled drug licensing system. This is the mechanism through which the CBPM regime operates, and through which companies obtain licences to manufacture or research controlled substances.

The Medicines and Healthcare Products Regulatory Agency (MHRA)

The MHRA is the principal medicines regulator. It grants marketing authorisations for licensed cannabis medicines, accepts and monitors CBPM imports, and enforces the prohibition on advertising or promoting unlicensed CBPMs. It exercises criminal investigation powers and has signalled a shift towards more robust enforcement, including civil injunctions and prosecution for serious breaches.

The Care Quality Commission (CQC)

The CQC is the independent regulator of health and social care in England. In the cannabis context, it regulates and inspects the private clinics through which the vast majority of CBPM prescriptions are issued. It monitors compliance with safety and quality standards, including the management of controlled drugs, and publishes an annual controlled drugs update. Its 2024 report (published on 15 July 2025) highlighted a 130% rise in private CBPM prescriptions and raised concerns about inconsistent prescribing practices, inadequate clinical governance, and poor communication between clinics, pharmacies and GPs. The CQC has no cannabis-specific regulatory framework; clinics are assessed under the same standards applicable to all independent healthcare providers.

The Food Standards Agency (FSA)

The FSA regulates consumer CBD products as novel foods under the UK’s novel food framework. Businesses wishing to sell CBD food supplements must submit a novel food authorisation application; only products linked to a validated application submitted before 31 March 2021 may remain on sale pending full authorisation. As of mid-2025, approximately 5,000 products had advanced to the risk management review stage. The FSA has established a new acceptable daily intake of 10 mg CBD for healthy adults, significantly below the previous 70 mg guideline, causing considerable industry concern.

The National Institute for Health and Care Excellence (NICE)

NICE determines whether cannabis medicines are prescribed through the NHS by assessing cost-effectiveness and clinical evidence. Its guidance currently restricts NHS CBPM-prescribing to four indications – chemotherapy-induced nausea, MS spasticity, severe treatment-resistant epilepsy, and tuberous sclerosis complex – demonstrating the importance of its role as the principal gatekeeper to NHS access.

Self-regulation in the UK cannabis and psychedelic medicines sector is fragmented and subordinate to a robust statutory framework. None of the bodies below has legal enforcement powers. The absence of a single consolidated self-regulatory body with genuine disciplinary authority is a significant structural gap, increasingly apparent as the private CBPM market expands.

The Association of the British Pharmaceutical Industry (ABPI)

The ABPI governs clinical trial transparency and good clinical practice for member companies through its Code of Practice, enforced by the independent PMCPA – the most developed disciplinary mechanism in the sector.

The Cannabis Industry Council (CIC)

The CIC is the leading medical cannabis trade body. It publishes industry guidance, commissions research, and represents the sector in engagement with government, the MHRA, NHS England and the ACMD. It has no power to sanction members.

The Medical Cannabis Clinicians Society (MCCS)

The MCCS publishes Good Practice Guidelines for CBPM prescribers covering consultation requirements, multidisciplinary team expectations, and recommended dosages and strengths of prescribed cannabis flower. Compliance is entirely voluntary – no mandated training exists for CBPM prescribers – and the CQC has identified the resulting variation in prescribing practice as a patient safety concern.

The Cannabis Trades Association (CTA)

The CTA represents businesses across the CBD, hemp and medicinal cannabis sectors. It is UK-centric with European and international members.

Drug Science

Drug Science is an independent charity running Medical Cannabis and Medical Psychedelics Working Groups. It publishes research, engages with the ACMD and Parliament, and operates the Project TWENTY21 real-world evidence platform. It has no regulatory oversight.

Clinical Trials

For clinical trials, Research Ethics Committees within the Health Research Authority framework provide independent ethical oversight of all investigational medicine trials, including CBPMs and psychedelics.

The CBPM Market

The UK medical cannabis sector has grown from a standing start in November 2018 to a market serving an estimated 50,000–100,000 patients as of early 2026. Private prescription volumes are rising at rates exceeding those of mainstream pharmaceuticals.

However, despite the apparent growth of the market, the practical consequence of the 2018 framework has been the emergence of a substantial private-sector market operating alongside a near-negligible NHS prescribing volume. NHS prescriptions for unlicensed CBPMs have averaged fewer than five items per month since 2018. By contrast, private prescriptions rose approximately tenfold between 2020 and 2021 and continued to double annually. The CQC reported a further 130% increase in 2023–2024, with approximately 346,600 items prescribed in the year to March 2024.

This growth has been driven by 20–30 CQC-regulated private clinics which have expanded rapidly to serve estimated patient numbers of between 50,000 and 100,000 as of early 2026. Conditions commonly treated include chronic pain, epilepsy, MS, PTSD, anxiety disorders, and Crohn’s disease. Monthly medication costs run to GBP150–GBP500 plus consultation fees.

Patient groups and clinicians have been vocal in their criticism of the two-tier nature of the system, which effectively restricts lawful CBPM access to those with the financial means to pay for private treatment. The principal barriers to NHS access are:

• the limited range of NICE-approved indications;
• the absence of UK-based data from randomised controlled trials (RCTs) acceptable to NICE; and
• structural barriers to GP involvement.

The Psychedelics Market

No legal psychedelic medicines market yet exists in the UK, save for the small private ketamine therapy sector. However, the research and pre-commercial landscape is active. Imperial College London and King’s College London host world-leading research programmes. Companies including COMPASS Pathways (psilocybin for treatment-resistant depression) have raised significant capital and conducted trials at UK sites. The commercial opportunity in psychedelic medicines is widely regarded as substantial: treatment-resistant depression affects millions in the UK; PTSD treatment remains inadequate, and patients requiring addiction medicine are underserved.

Research Barriers

The Schedule 1 status of cannabis, THC, psilocybin, LSD, MDMA and DMT creates a significant practical obstacle to research. Universities and hospitals wishing to conduct clinical trials must obtain a Schedule 1 licence from the Home Office – a process that adds substantial cost, delay and administrative overheads. This is a direct constraint on the UK’s ability to develop an evidence base for psychedelic-assisted therapies. The 2023 Home Affairs Committee recommended the government move psychedelic drugs to Schedule 2 in order to facilitate research, and multiple members of parliament signed an open letter to the Home Office calling for rescheduling “without delay”.

Prescribing Bottleneck

Only GMC Specialist Register doctors may initiate CBPM prescriptions, creating significant access constraints and concentrating prescribing within a small number of private clinics.

NHS Access

NICE guidance restricts NHS funding to four indications. Without UK-based randomised controlled trial data acceptable to NICE, broader NHS commissioning remains effectively closed, leaving patients dependent on costly private prescriptions.

Regulatory Fragmentation

No single consolidated legislative framework governs cannabis. Businesses must navigate the MDA, MDRs, HMRs, novel food rules, cosmetics regulations, advertising law and controlled drug licensing simultaneously, with significant areas of law untested in the courts.

POCA Exposure

UK investors in overseas cannabis businesses face money laundering risk under the Proceeds of Crime Act 2002 (POCA), as proceeds of activities lawful abroad but criminal in the UK can constitute criminal property.

Banking and Finance

POCA sensitivity makes UK banks reluctant to service cannabis businesses, creating persistent difficulties in accessing basic financial services.

Supply Chain Instability

Most prescribed CBPM flower is imported, creating stock availability issues, expiry problems, and lack of continuity for patients.

Corporate and Financial Crime Overlay

For businesses and investors operating in the cannabis and psychedelic medicines space, the criminal law exposure extends well beyond the MDA, MDRs and HMRs (considered previously). Several general corporate criminal law regimes are engaged.

Corporate criminal liability

Under the existing identification doctrine, a company can be criminally liable where the commission of an offence can be attributed to a senior manager of the company. Individual officers – directors, managers and company secretaries – who consent to, connive at, or by neglect facilitate an offence may be personally prosecuted under both the MDA and the HMRs.

Money laundering

The proceeds of controlled drug offences are criminal property for the purposes of POCA. This has significant implications for banks, investors and professional advisers who handle funds derived from cannabis or psychedelic activities, even where those activities are lawful in the jurisdiction where they occur.

Bribery

The Bribery Act 2010 creates offences of active and passive bribery, and a separate corporate offence of failing to prevent bribery. Given the regulatory intensity of this sector, relationships with government officials and regulatory bodies require particular care.

Fraud

The Fraud Act 2006 is potentially engaged where products are misrepresented as to their composition, potency or legal status, or where false or misleading statements are made to regulators. The MHRA has pursued fraud charges against operators who have made false representations in regulatory submissions.

POCA and Investment Risk

A particularly challenging dimension of the psychedelic medicines space for UK-based investors and businesses is the application of POCA to overseas activities. POCA creates money laundering offences in respect of “criminal property” – defined as the proceeds of conduct that would constitute a criminal offence in England and Wales, even where that conduct occurs abroad and is lawful in the jurisdiction where it takes place.

This creates a significant trap for UK investors in overseas cannabis and psychedelic businesses. Investing in a psilocybin retreat in Jamaica (where psilocybin is not controlled), or acquiring shares in a licensed psilocybin therapy company in the Netherlands or Australia, potentially constitutes handling the proceeds of conduct that would be a Class A drug offence in the UK. The statutory defence that the conduct was not criminal in the jurisdiction where it occurred does not apply where the equivalent UK offence would carry more than 12 months’ imprisonment – which, for Class A supply offences, is plainly the case. Banks, advisers and professionals handling such funds face parallel liability.

Specific Risks for Corporate Market Participants

Companies operating in the CBPM, CBD or psychedelic medicines space face a distinct risk profile. Key issues include: 

• advertising unlicensed CBPMs or making therapeutic claims without marketing authorisation – an offence under the HMRs regardless of the accuracy of the claim;
• supplying or dispensing CBPMs without adequate clinical governance – the CQC and General Pharmaceutical Council (GPhC) have both signalled increased scrutiny, including through targeted inspections of private CBPM clinics and pharmacies;
• supply chain and import compliance – including MHRA import acceptance, GMP standards, and correct labelling and documentation; 
• banking and financial services – POCA sensitivity has made UK banks notably cautious, and many cannabis businesses still struggle to access basic banking services; and
• employment law – employees using CBPMs may face workplace drug testing issues, and employers should have clear, legally compliant policies.

Enforcement Agencies

Multiple agencies share enforcement responsibility, with jurisdiction depending on the nature of the alleged breach.

MHRA

The MHRA is the principal enforcement body for medicines offences. It conducts criminal investigations, executes search warrants, seizes goods and prosecutes under the HMRs. It has signalled a shift towards more robust enforcement, including formal cautions, civil injunctions and criminal prosecution for serious or repeated breaches.

The MHRA has signalled as a priority area the diversion of prescription-only medicines from the regulated supply chain, as well as the manufacture and supply of unlicensed medicines and the making of false representations to regulators. Its enforcement record includes substantial confiscation proceedings: the order against David Noakes, director of a company manufacturing unlicensed GcMAF products, requiring payment of GBP1.4 million following conviction under the HMRs and for money laundering is illustrative.

The Home Office

The Home Office enforces controlled drug licensing requirements under the MDA and MDRs through the DFLU. Licence breaches may trigger revocation, refusal of renewal, and criminal prosecution.

The Police and the National Crime Agency (NCA)

The Police and NCA prosecute MDA offences including possession, supply, cultivation and importation. The Crown Prosecution Service (CPS) conducts prosecutions in England and Wales; the Public Prosecution Service Northern Ireland (PPS NI) does so in Northern Ireland.

HMRC and UK Border Force

HMRC and UK Border Force enforce import and export controls, routinely seizing cannabis and CBD products suspected of breaching national laws.

Trading Standards

Trading Standards enforces consumer product law, food labelling, and novel food rules for CBD products. The Advertising Standards Authority (ASA) acts against unauthorised health claims in marketing materials.

Penalties

Under the MDA, penalties for cannabis offences reflect its Class B status. Possession carries up to five years’ imprisonment and an unlimited fine. Supply, production and cultivation carry up to 14 years, as do importation and exportation. In cases involving financial benefit, confiscation proceedings may follow, with orders potentially far exceeding actual profits.

Psychedelic substances classified as Class A controlled drugs can attract sentences of up to life imprisonment for production and supply, and up to seven years for simple possession.

Under the HMRs, the most serious medicines offences carry up to two years’ imprisonment and unlimited fines. Where proceeds of crime are involved, asset freezing, civil recovery and restraint orders are available in addition to any criminal penalty.

International Treaty Framework

The UK is a signatory to the three principal international conventions governing controlled drugs:

• the UN Single Convention on Narcotic Drugs 1961;
• the Convention on Psychotropic Substances 1971; and
• the UN Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1988.

These treaties constrain the extent to which the UK can liberalise its domestic drug laws. Both cannabis and psilocybin are listed in the most restrictive schedules under the 1971 Convention, though psilocybin mushrooms (as distinct from the isolated compound) were not specifically included.

On 2 December 2020, the UN Commission on Narcotic Drugs voted to remove cannabis and cannabis resin from Schedule IV of the 1961 Convention – the most restrictive category. This is expected to alleviate issues with access for medical and scientific purposes, though cannabis extracts (including CBD extracts) were left in Schedule I. The UN framework does not prevent rescheduling of substances for medical purposes within domestic law, as the Australian experience confirms.

Post-Brexit Regulatory Divergence

The UK’s departure from the EU (“Brexit”) has created regulatory divergence in several respects relevant to this sector. Most significantly, the UK MHRA now operates an independent marketing authorisation process, separate from the European Medicines Agency (EMA). Products approved by the EMA are not automatically approved in the UK, creating potential divergence in the range of licensed medicinal cannabis products available in each market.

Multi-site European clinical trials previously benefited from the EU Clinical Trials Regulation framework. Post-Brexit UK trial sites operate under the UK Clinical Trial Regulations, creating additional administrative burden for sponsors. The FSA novel food authorisation framework for CBD products is also now independent of the EU/EFSA process: UK applications are assessed separately, and the status of a product in the EU does not determine its status in the UK.

POCA and Overseas Activities: the Critical Risk

In the context of cannabis and psychedelics, the interaction of POCA with overseas activities presents the most legally complex and commercially significant cross-jurisdictional issue in this sector. Part 7 of POCA makes it an offence to deal in “criminal property” – broadly, the proceeds of conduct that would constitute a criminal offence in England and Wales. Because cannabis is a Class B controlled drug in England and Wales, the proceeds of cannabis sales in jurisdictions where cannabis is lawful – including Canada, Germany and a growing number of US states – can potentially constitute criminal property in the hands of a UK person who handles them knowing or suspecting them to be such proceeds. 

The POCA provisions have been the subject of sustained criticism, and the Home Office has acknowledged that they create uncertainty for legitimate UK commercial activity. However, as of April 2026, no legislative amendment has been made. UK banks have been notably cautious about banking cannabis-related businesses as a result.

For civil recovery purposes – under Part 5 of POCA – the position is somewhat different: the conduct must also have been unlawful where it occurred. This distinction matters to the analysis of asset freezing and forfeiture proceedings, but does not assist with the money laundering offences in Part 7. Investors, operators and professional advisers must treat this area with the greatest caution.

International laws and developments affect UK access in several important ways. The UK’s medical cannabis market is structurally dependent on overseas supply: the main suppliers are Canada, Spain and Portugal, meaning regulatory or operational disruptions abroad directly affect UK patients – as demonstrated when raids on licensed facilities in Portugal in May 2025 caused over 25 tonnes of cannabis to sit in limbo, disrupting European supply chains including the UK’s. 

Brexit has compounded this by severing automatic regulatory recognition: companies holding EMA authorisation must now conduct a separate MHRA application to access the UK market, doubling the regulatory burden and effectively pricing smaller operators out unless the commercial opportunity justifies standalone UK investment. Per-shipment Home Office import licensing creates additional supply gaps for patients.

On the reform side, international developments are the principal evidence cited by domestic advocates pushing for change. Australia’s legalisation of psilocybin and MDMA-assisted therapy, the Czech Republic’s decision to permit medical psilocybin from January 2026, and Germany’s phased cannabis legalisation from 2024 are all actively referenced in UK parliamentary debate. At the international treaty level, the 2020 UN decision to remove cannabis from the most restrictive schedule of the Single Convention removed a key legal obstacle to further UK rescheduling, widening the space for domestic reform within existing treaty obligations.

In 2025, the Minister of State for Policing and Crime commissioned the ACMD to assess whether the 2018 legislative changes achieved their intended outcomes, including whether rescheduling CBPMs had the desired impact, any unintended consequences, and the inhibiting effect that private prescriptions may have had on the clinical trials necessary for NHS access. A public call for evidence ran from September to October 2025. The report’s findings are expected to inform future regulatory policy and could lead to changes via statutory instrument. NICE reviewed its cannabis-based medicinal products guidelines in May 2025 and made no substantive change in practice.

Also in 2025, the government enabled research with Schedule 1 drugs – including psilocybin and MDMA – without the requirement for a controlled drugs licence, to be evaluated through a pilot scheme. A new cross-government working group was established to oversee implementation via a pilot scheme. This is the most significant step in psychedelics policy in decades, removing the principal barrier that had driven clinical trials to other European jurisdictions.

The government recently proposed reclassifying ketamine to Class A. However, the ACMD concluded that ketamine should not be reclassified and should remain Class B, noting that acute harms align with its current classification and that a public health-centred approach is essential for reducing ketamine-related harms. This is a significant outcome for therapeutic ketamine use, as Class A reclassification would have substantially curtailed ketamine-assisted therapy clinics currently operating off-label for depression.

In January 2019, CBD was added to the European Commission’s novel food catalogue. The UK Food Standards Agency (FSA) aligned its position with this classification, setting a deadline of 31 March 2021 for businesses to submit valid novel food authorisation applications in order for their products to remain lawfully on the market. As of mid-2025, approximately 5,000 CBD products had advanced into the FSA’s risk management review phase, and eight CBD dossiers had cleared the safety assessment hurdle. In 2025, the FSA established a new acceptable daily intake (ADI) of 10 mg of CBD for healthy adults – a significant reduction from the previous 70 mg guideline – which has been met with concern by industry stakeholders.

A public consultation closed in November 2025, seeking stakeholder input on the terms of authorisation for several applications that passed the safety assessment. However, Food Standards Scotland must run a separate consultation before all four nations can align and recommendations proceed to ministers. The FSA remains on track to make ministerial recommendations in autumn 2026; however, Food Standards Scotland has cautioned that this is the earliest achievable. Only formally authorised products will ultimately remain on the market.

Several legislative routes currently exist without the need for primary legislation. The most significant is amendment by Statutory Instrument under the MDRs, the mechanism used in 2018 and the most likely vehicle for any future expansion of prescribing rights or scheduling changes. The ongoing ACMD review of the 2018 cannabis rescheduling could produce recommendations implementable by this route, covering broader prescriber eligibility or improved NHS access frameworks. For psychedelics, the July 2025 government decision to pilot the removal of the controlled drugs licence requirement for Schedule 1 research is already in effect via this route, and full rescheduling of psilocybin to Schedule 2 remains achievable the same way.

Private Members’ Bills have been used to build parliamentary pressure on NHS access, though they rarely pass without government support. Where companies obtain full MHRA marketing authorisation for specific products, this remains the gold standard route to routine NHS prescribing for both cannabis-based medicines and, eventually, psychedelic medicines.

The likelihood of a regulated adult-use recreational cannabis market in the UK is low in the near term. The current Labour government has not proposed adult-use legislation, and no legalisation bill is before Parliament. The government immediately rejected the London Drugs Commission’s May 2025 recommendation to decriminalise personal possession by moving cannabis from the Misuse of Drugs Act to the Psychoactive Substances Act. In practice, Police and Crime Commissioners are implementing diversion schemes that keep cannabis users out of the criminal justice system – decriminalisation by stealth – although practices vary significantly depending on region and local police policy. A regulated market remains a late 2020s prospect at the earliest. There are no moves towards recreational legalisation of psychedelics whatsoever.